Latest Biotherapeutics News

Wound Care Publication to be Distributed Within USA Today Highlights Advancements In The Industry and Inspirational Survival Story From J.R. MartinezNEW YORK, May 25, 2012 /PRNewswire/ -- Mediaplanet Publishing, the global leader in theme media, today publishes Wound Care, an eight-page section distributed within the USA Today newspaper. Reaching over 2 million readers, the special section will appear within USA Today in the high-impact markets of New York, New England, North and South Carolina, and Southern Florida with the help of a number o...

Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory BoardCRANBURY, N.J., May 25, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today that it has filled two important leadership positions with established biopharmaceutical industry experts. Stephen J. McAndrew, Ph.D. is now Vice President, Business Development and Vincent J. Benn, Ph.D. has joined the company as Vice President, Clinical & Regulatory Affairs. The company also announced its n...

Dyax Launches HAE Diagnostic Testing Refund Program to Encourage Proper Diagnosis and Disease ManagementDyax Corp. (NASDAQ: DYAX) the manufacturer of KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older, has announced the launch of its HAE diagnostic testing refund program. The program is designed to help eligible patients cover the out-of-pocket costs associated with HAE diag...

Ventria Bioscience to Participate in Business Partnering Program at 2012 BIO International ConventionFORT COLLINS, Colo. – May 23, 2012 – Company representatives from Ventria Bioscience will attend the 2012 BIO International Convention June 18 – 21 at the Boston Convention & Exhibition Center (Boston, Mass.). As in past years,...

Karolinska University Hospital and GE Healthcare collaborate to advance technologies for cell therapy.

Pioneering three-year study will investigate technology and workflow needs in a clinical setting Stockholm, Sweden and Chalfont St Giles, UK – 22 May 2012 – Karolinska University Hospital Sweden and GE Healthcare Life Sciences today announced a joint research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell t...

Karolinska University Hospital and GE Healthcare Collaborate to Advance Technologies for Cell TherapyKarolinska University Hospital Sweden and GE Healthcare Life Sciences today announced a joint research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell therapy. The three year collaboration

Eleven Biotherapeutics: closer to the clinic with a protein for topical delivery in dry eyeEleven Biotherapeutics claims to be 'turning up the dial' on protein therapeutics. Mark Levin, one of the company's founders and it first acting CEO drew inspiration for the company's name from the 1984 mock rockumentary 'This is Spinal Tap', the.......

Northwest Bio Provides Update On DCVax®-L Brain Cancer TrialBETHESDA, Md., May 17, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) announced today that it now has 41 clinical trial sites open and recruiting across the United States in its ongoing clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. This is ahead of the Company's previous projection of 40 sites b...

Data from Jennerex JX-594 clinical trials on cancer to be presented at ASCO annual meetingJennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus ther...

ZOLL Honored for Excellence in Customer Satisfaction for 11th Consecutive YearZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it is the only company to receive the NorthFace ScoreBoard Award℠ for ‘world class’ excellence in customer satisfaction for the 11th consecutive year. Now in its 12th year, the award is presented annually by Omega Management Group Corp.,...

Jennerex Announces Data Presentations Relating to Oncolytic Virus JX-594 at American Society of Clinical Oncology Annual MeetingSAN FRANCISCO, Calif., May 16, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer will be covered in three separate abstracts released today by the American Soc...

44-Year-Old Father Playing in a Charity Football Match Saved by Bystander CPR and ZOLL AEDZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, reported today that a 44-year-old father playing in a Sports Relief Charity Football Match in Devon, England, was saved with CPR and a ZOLL AED Plus® when he collapsed during the second half of the game. Chris Richards, who operates a first ai...

Hematech Biotherapeutics Inc., Prometic deal

Eleven Biotherapeutics preclinical data

Eleven Biotherapeutics financial update

Dyax Corp. Launches Hereditary Angioedema (HAE) Attack Tracker™, a Free iPhone Application for HAE PatientsDyax Corp. (NASDAQ: DYAX) today announced the launch of a free smartphone application for the iPhone – HAE Attack Tracker™. This application allows HAE patients to keep detailed records of their disease related information, including emergency and physician contacts as well as individual attack data. “Recording and tracking triggers a...

Eleven Biotherapeutics secures $20 million Series A financingEleven Biotherapeutics, Inc, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics, has secured $20 million in Series A equity financing, expanding the company’s total Series A investment to $4...

Protalix BioTherapeutics to Present at Three Upcoming Healthcare ConferencesCARMIEL, Israel, May 10, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX) (TASE:PLX), today announced that senior management will present at three upcoming conferences. Details regarding the conferences are as follows: Oppenheimer 13th Annual Israeli Conference Sunday, May 13, 2012 at 1:00 PM IDT David Intercontinental Hotel, Tel-...

AMAG Pharmaceuticals Appoints William Heiden as President and Chief Executive OfficerAMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the appointment of William K. Heiden as president and chief executive officer, effective May 14, 2012. Mr. Heiden, age 52, has also been appointed to the company’s board of directors. AMAG also announced that its largest shareholder, Adage Capital, has requested and the company has agreed to allo...

Elelyso: a new therapeutic option for patients with Gaucher diseaseThe US Food and Drug Administration recently approved Protalix BioTherapeutic's (NYSE-AMEX: OLX) Elelyso (taliglucerase alfa), a new enzyme replacement therapy (ERT) that provides patients with Gaucher disease, which will be marketed by global drugs...

ProMetic licenses plasma-derived orphan drug to HematechProMetic Life Sciences granted Hematech Biotherapeutics the right to manufacture a plasma-derived orphan drug using its plasm -More-

Eleven secures $45 million to advance therapeutic proteinEleven Biotherapeutics raised $20 million from investors, bringing its Series A total to $45 million. -More-

Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland (News)02 May 2012: Oxford, UK - Oxford BioTherapeutics (OBT) today announces the appointment of Dr Esteban Pombo-Villar as Chief Operations Officer (COO) of the OBT group. In this position he will ...

Nature: Drug-making plant blooms - featuring VentriaDrug-making plant blooms Approval of a ‘biologic’ manufactured in plant cells may pave the way for similar products. BY AMY MAXMEN It was midnight when an anxious Ari Zimran finally got the phone call for which he had been waiting. The n...

Eleven raises $10M in series A extensionEleven Biotherapeutics Inc. (Cambridge, Mass.) raised $10 million in an extension of a series A round, bringing the total raised in the round to $45 million. New investor JAFCO joined existing investors Third Rock Ventures and Flagship Ventures. The...

0 1 2 3 4 ›»

buy Biotherapeutics market research data and corporate reports now Advertisement